Delivery Order SPE2DB24D2101-SPE2DB25FKNVY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $10,368.01. This is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was awarded competitively with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Tamsulosin HCL 0.4 mg capsules in a quantity of 1,000 units, with a ceiling value of $1,441.15. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a common medication used to treat benign prostatic hyperplasia. This firm fixed-price delivery order, valued at $11,771.03, is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive procedures with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, with a contract ceiling value of $1,727.65. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by August 8, 2025. The award represents a routine pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. This competitive delivery order, valued at $2,750.29 with firm fixed pricing, was awarded on August 6, 2025, with an ultimate completion date of August 7, 2025. The contract includes no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $24,188.72. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 16, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. The contract, awarded on August 18, 2025, carries a ceiling value of $2,029.15 with a firm fixed price structure and an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This was a competitively awarded...
- The Defense Logistics Agency awarded a $9,621.08 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules. This contract is structured as a firm fixed price delivery order with an ultimate completion date of September 17, 2025, and represents a non-set-aside competitive award. The pharmaceutical will be supplied from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $7,776.80 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of July 23, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's ongoing pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tamsulosin HCL 0.4 mg capsules in a quantity of 500 units, with a ceiling value of $2,217.99. This competitively awarded, non-set-aside contract utilizes firm fixed price terms and carries an ultimate completion date of July 23, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNVYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $2,702.16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical procurement standards. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion blanket purchasing agreement extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of medications, medical devices, and healthcare commodities to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The current delivery order for Tamsulosin HCL—a medication commonly used to treat benign prostatic hyperplasia—exemplifies the routine pharmaceutical resupply operations conducted through this prime vendor relationship.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 8/25/25 |